Wounds, Gunshot

In addition, the program will work to assess biofilm control, biomarker monitoring and healing in acute trauma situations such as blasts, burns, and gunshot wounds that occur in civilian and military settings 3M Center. (Credit: 3M) 3M Health Care’s Medical Solutions Division, the world leader in advanced wound care, was awarded $34.2 million from the U.S. Army Medical Research Acquisition Activity to develop a range of new solutions for infection prevention, wound management and wound healing. 3M will lead a program focused on treatment strategies that can be used in austere settings, especially those related to mass casualty and delayed evacuation situations — a critical objective of the Department of Defense Combat Casualty Care Capability Assessment. In addition, the program will work to assess biofilm control, biomarker monitoring and healing in acute trauma situations such as blasts, burns, and gunshot wounds that occur in civilian and military settings. 3M will collaborate with the University of Minnesota Medical School, the 59th Medical Wing Science & Technology Office of the Chief Scientist (59MDW/ST, lead military partner), Naval Medical Research Unit-San Antonio (NAMRU-SA) and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) in this program. The awarded funding will support four separate product solutions, with studies that range from prototype and formulation development to completion of two clinical studies to be used for product registration. “Successful treatment of acute, traumatic wounds requires a continuum of care that begins with easy-to-use dressings and effective infection prevention that can be applied at the point of injury, continues with portable solutions for transport, and transitions to more sophisticated solutions in hospital settings suitable for rehabilitation and reintegration of patients,” said Raymond Chiu, senior vice president, research & development, 3M Health Care Business Group.  “3M is proud to be working with civilian and military partners to bring these solutions to fruition.” The planned work involves at least six principal investigators leading studies at three different sites across the United States.  Over 125 support personnel will be involved in the research efforts to be performed over the FY 2023 – FY 2027 award period. Addressing and stabilizing traumatic injuries in the field requires fast, effective and easy-to-use solutions that provide more capability at the point of injury.  The novel solutions developed and demonstrated in this program will also be well suited for use in civilian traumatic, burn and chronic wound care. The U.S. Army Medical Research Acquisition Activity, 808 Schreider Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office.  In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture. This work [is] was supported by the Office of the Assistant Secretary of Defense for Health Affairs, in the amount of $34,191,124, through the Defense Health Agency Expeditionary Medicine Research and Development Program under Award No. HT94252320059. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. Source: Company Press Release

3M (NYSE: MMM) + Health Care announced that its Medical Solutions Division received a $34.2 million award from the U.S. Army Medical Research Acquisition Activity. The award enables 3M to develop a range of new solutions for infection prevention, wound management and wound healing. St. Paul, Minnesota-based 3M plans to lead a program focused on treatment strategies for use in austere settings. This includes those related to mass casualty and delayed evacuation situations. Additionally, 3M expects its program to assess biofilm control, biomarker monitoring and health in acute trauma situations. It highlighted blasts, burns and gunshot wounds occurring in civilian and military settings. 3M will collaborate with the University of Minnesota Medical School, the 59th Medical Wing Science & Technology Office of the Chief Scientist (59MDW/ST, lead military partner), Naval Medical Research Unit-San Antonio (NAMRU-SA) and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) in this program. The award supports four separate product solutions. Studies range from prototype and formulation development to clinical studies for product registration. The company plans to have at least six principal investigators leading studies at three U.S. sites. 3M’s program includes more than 125 support personnel for research efforts between 2023 and 2027. “Successful treatment of acute, traumatic wounds requires a continuum of care that begins with easy-to-use dressings and effective infection prevention that can be applied at the point of injury, continues with portable solutions for transport, and transitions to more sophisticated solutions in hospital settings suitable for rehabilitation and reintegration of patients,” said Raymond Chiu, SVP, R&D, 3M Health Care.  “3M is proud to be working with civilian and military partners to bring these solutions to fruition.”

ST. PAUL, Minn., Jan. 10, 2024 /PRNewswire/ -- 3M Health Care's Medical Solutions Division, the world leader in advanced wound care, was awarded $34.2 million from the U.S. Army Medical Research Acquisition Activity to develop a range of new solutions for infection prevention, wound management and wound healing. 3M will lead a program focused on treatment strategies that can be used in austere settings, especially those related to mass casualty and delayed evacuation situations -- a critical objective of the Department of Defense Combat Casualty Care Capability Assessment. In addition, the program will work to assess biofilm control, biomarker monitoring and healing in acute trauma situations such as blasts, burns, and gunshot wounds that occur in civilian and military settings. 3M will collaborate with the University of Minnesota Medical School, the 59th Medical Wing Science & Technology Office of the Chief Scientist (59MDW/ST, lead military partner), Naval Medical Research Unit-San Antonio (NAMRU-SA) and The University of Texas Health Science Center at San Antonio (UT Health San Antonio) in this program. The awarded funding will support four separate product solutions, with studies that range from prototype and formulation development to completion of two clinical studies to be used for product registration. "Successful treatment of acute, traumatic wounds requires a continuum of care that begins with easy-to-use dressings and effective infection prevention that can be applied at the point of injury, continues with portable solutions for transport, and transitions to more sophisticated solutions in hospital settings suitable for rehabilitation and reintegration of patients," said Raymond Chiu, senior vice president, research & development, 3M Health Care Business Group. "3M is proud to be working with civilian and military partners to bring these solutions to fruition." The planned work involves at least six principal investigators leading studies at three different sites across the United States. Over 125 support personnel will be involved in the research efforts to be performed over the FY 2023 – FY 2027 award period. Addressing and stabilizing traumatic injuries in the field requires fast, effective and easy-to-use solutions that provide more capability at the point of injury. The novel solutions developed and demonstrated in this program will also be well suited for use in civilian traumatic, burn and chronic wound care. The U.S. Army Medical Research Acquisition Activity, 808 Schreider Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. In conducting research using animals, the investigator(s) adheres to the laws of the United States and regulations of the Department of Agriculture. This work [is] was supported by the Office of the Assistant Secretary of Defense for Health Affairs, in the amount of $34,191,124, through the Defense Health Agency Expeditionary Medicine Research and Development Program under Award No. HT94252320059. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. About 3M 3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news. SOURCE 3M Company